Tourette syndrome is a neuropsychiatric disorder with onset in childhood. New therapies are needed to effectively manage and treat this condition. Gut microbiota can affect central physiology and function via the microbiota-gut-brain axis. Here, we report a case in which fecal microbiota transplantation (FMT) is used to treat a child with Tourette syndrome, whose symptoms ameliorated dramatically in the following eight weeks.
Tourette syndrome (TS) is a neurobehavioral disorder that has occurred in childhood, and it is defined by the presence of both multiple motor tics and one or more phonic tics for more than 1 year and never tic‐free for more than 3 consecutive months [
Previous studies have reported abnormalities in the cortico-basal ganglia-thalamo-cortical loops in patients with Tourette syndrome [
A 9-year-old boy with TS was admitted to our hospital. His symptoms predominantly consisted of involuntary eye turning, headshaking, shrugging, and voice tics, which he had experienced for 2.5 years. He was diagnosed as deficient in trace elements at a local hospital and received oral calcium tablets, with no relief of symptoms. After 6 months, the patient experienced an aggravation of the abovementioned symptoms, accompanied by trembling limbs, inattention, and memory impairments. The patient received herbal medicine (not detailed in clinical notes), but this was ineffective.
One year ago, the patient visited our hospital and was diagnosed with TS. He had a negative result for antistreptolysin O titers (ASOTs). He was prescribed tiapride 100 mg tid and probiotics, including
A thorough assessment indicated that the patient was in a good conscious state, with normal muscle tension and physical strength. Physiological reflexes were present, and pathological reflexes were not elicited. In terms of relevant personal history, the patient had fallen downstairs and broke his head at the age of 3 years. In terms of family history, his grandfather’s brother had congenital dementia. Laboratory investigations indicated no restrictions on treatment, and allergen detection did not find any inhalation allergens or food allergens. We described the treatment process of FMT and possible adverse reactions to the patient and his parents, and his father signed the consent form.
Healthy volunteers (between 10 and 40 years old) received a preliminary screening by a screening questionnaire for family history and individual disease history and then took a laboratory examination for common pathogens, including human immunodeficiency virus, hepatitis A, B, and C virus,
The fecal microbiota suspension was collected from a healthy 14-year-old male donor under rigorous screening and prepared in vitro. FMT was then administered to the patient’s small intestine with 100 ml of fecal suspension via gastroscopy and to the colon with 300 ml of fecal suspension via colonoscopy under anaesthesia. There was no obvious abnormality found during endoscopy. The process of FMT treatment did not cause adverse problems, such as aspiration, vomiting, fever, abdominal pain, abdominal distension, or other adverse reactions. No abnormal clinical or biological parameters were observed before or after FMT.
Following FMT, the patient kept using tiapride 100 mg tid. His YGTSS score was the primary indicator assessed before and after FMT treatment, and we also recorded clinical evaluations and life behaviour observations of the patient (from his primary caregiver). Eight weeks after treatment, the patient’s YGTSS total tic severity score decreased from 31 to 5, his motor severity score fell from 16 to 5, and his vocal severity score fell from 15 to 0, shifting from severe to mild. The boy’s parents reported that the severity of their son’s tic symptoms had clearly ameliorated. They reported that involuntary phonation had disappeared, and involuntary shrugging now occurred only occasionally. In addition, his attention was much more focused.
Here, we report the case of a patient with TS, tentatively prescribed with tiapride and probiotics at first, which alleviated severity of the patient’s symptoms. However, the patient experienced a relapse of symptoms, and tiapride and probiotics could not achieve remission again. Subsequently, we introduced FMT to the patient, which dramatically ameliorated his tic symptoms.
This case shows evidence for significant efficacy and safety when treating TS with FMT, suggesting that rebalancing GI microbiota might offer a promising new biological therapy for TS. However, long-term efficacy and potential adverse reactions remain unclear and warrant randomized clinical trials with large samples. The interaction between the gut and the brain remains unclear. Previous studies have indicated that the brain-gut pathway is bidirectional and that there is potentially a complex relationship between the gut microbiota and the brain [
The authors declare that there are no conflicts of interest regarding the publication of this paper.
Yunsheng Yang and Liping Zou contributed to the study concept and design. Liping Zou, Huijun Zhao, and Xi Luo collected the clinical samples and performed the assessment. Yunsheng Yang, Lihua Peng, Yichao Shi, and Huijun Zhao performed the treatment. Yunsheng Yang and Huijun Zhao wrote the manuscript. Yunsheng Yang and Liping Zou supervised the study together.
This study was supported by the National High-Tech Research and Development Projects (863), no. 2015AA020701, Key Technology for gut microbiota.